诺维本联合希罗达方案与紫杉醇、顺铂方案治疗晚期乳腺癌的疗效对比  

Comparison of therapeutic effect between NF plan and TP plan in treatment of advanced breast cancer

作　　者：郭莉[1] 赵玲[1] 王晓红[1] 

机构地区：[1]哈尔滨医科大学附属第三临床医院内五科,黑龙江哈尔滨150081

出　　处：《现代生物医学进展》2008年第11期2069-2070,共2页Progress in Modern Biomedicine

摘　　要：目的:比较诺维本联合希罗达方案(NF方案)和紫杉醇联合顺铂方案(TP方案)治疗晚期乳腺癌的疗效及安全性。方法:将117例经病理证实的晚期乳腺癌患者随机分为两组,第一组66例采用紫杉醇135mg/m^2,第1天静点,顺铂20mg,第2-6天静点,21天为一个周期。第二组51例采用诺维本25mg/m^2,第1,8天静点,希罗达2500mg/m^2,每天2次,连服14天,21天为一个周期。两组均以三个周期为一个疗程,至少接受两个疗程化疗。结果:TP组总有效率为42-4%(28/66);NF组为60.8%(31/51),p<0.05。TP组中位无进展时间7.7个月,中位生存时间为16.6个月。NF组分别为10.3个月和22.1个月,p<0.05。恶心呕吐的发生率NF组明显低于TP组,p<0.05。其余不良反应发生率相近,p>0.05。所有不良反应均能耐受。结论:诺维本联合希罗迭方案疗效较好,可作为晚期乳腺癌首选治疗方案。Objective：To compare the therapeutic effect and security of NF and TP plans.Methods：A total of 117 patients with advanced breast cancer proved pathologically were divided into NF and TP groups.TP group （66 cases）was received paclitaxel 135 mg/m iv drip d1,cisplatin 20 mg/m^2,iv drip d2-6,the treatment were repeated every 3 weeks.NF group （51 cases）received navelbine 25 mg/m^2,iv drip d1,8,capecitabine 2500 mg/m^2,twice a day,d2-14,the treatment were repeated every 3 weeks,All parents received two cycles of the treatment at least.Results：The total effective rate was 42.4% （28/66）in TP group,but 60.8% （31/51）in NF group,p〈0.05. The median time of progression （TTP）was 7.7 months and the median survival time was 16.6 months in the TP group;in the NF group, the TTP was 10.3 months and the median survival time 22.1 months,p〈0.05.Nausea was more serious in TP group than in NF group, p〈0.05.There was no significant difference in the other side effects between the two groups.All side effects were tolerable.Conclusion： NF plan is still a firstly selected one for patients with advanced breast cancer.

关 键 词：诺维本 希罗达 紫杉醇 顺铂 晚期乳腺癌 疗效 

分 类 号：R737.9[医药卫生—肿瘤]